Twice yearly injectable 'lenacapavir' for HIV prevention has been designated as an orphan drug in South Korea.

The Ministry of Food and Drug Safety (MFDS) recently announced this through the new year's first orphan drug designation notification.

The drug is indicated 'In combination with other antiretroviral therapy, for treatment of patients with multidrug-resistant HIV-1 infection for whom cannot be treated with antiretrovirals.'

This drug, marketed under the product name as 'Sunlenca,' is a first-in-class long-acting HIV-1 capsid inhibitor that is subcutaneously administered every six months. It was approved in the United States and Europe in 2022 and has been prescribe